GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Bcl2l1 | affects expression | ISO | BCL2L1 (Homo sapiens) | 6480464 | CTD | Etoposide affects the expression of BCL2L1 protein | PMID:15215046 | Bcl2l1 | decreases response to substance | ISO | BCL2L1 (Homo sapiens) | 6480464 | CTD | BCL2L1 protein results in decreased susceptibility to Etoposide | PMID:11468182 | Bcl2l1 | multiple interactions | ISO | BCL2L1 (Homo sapiens) | 6480464 | CTD | [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of CTNNB1 protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [[[[Hyaluronic Acid binds to CD44 protein] which results in increased expression of and results in increased activity of EP300 protein] which results in increased acetylation of and results in increased activity of RELA protein] which results in increased expression of BCL2L1 protein] inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; [VCAM1 protein co-treated with IL4 protein] inhibits the reaction [Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein]]; BCL2L1 protein inhibits the reaction [Etoposide results in increased activity of CASP3 protein]; BCL2L1 protein inhibits the reaction [Etoposide results in increased degradation of PARP1 protein]; BCL2L1 protein results in decreased susceptibility to [Cisplatin co-treated with Etoposide]; Etoposide inhibits the reaction [BAX protein binds to BCL2L1 protein] | PMID:10620629 PMID:15917659 PMID:19047049 PMID:8840993 | | ||||||||||||||||||||||
| Go Back to source page | Continue to Ontology report |